

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/189856 A1

(43) International Publication Date
15 September 2022 (15.09.2022)

(51) International Patent Classification:

C07D 231/12 (2006.01) C07D 413/06 (2006.01)
C07D 233/64 (2006.01) C07D 413/12 (2006.01)
C07D 249/06 (2006.01) C07D 417/06 (2006.01)
C07D 263/32 (2006.01) C07D 417/12 (2006.01)
C07D 277/22 (2006.01) A61P 1/16 (2006.01)
C07D 333/10 (2006.01) A61P 13/12 (2006.01)
C07D 333/52 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(21) International Application Number:

PCT/IB2022/000106

(22) International Filing Date:

08 March 2022 (08.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

17/195,334 08 March 2021 (08.03.2021) US
17/219,058 31 March 2021 (31.03.2021) US

(71) Applicant: ABIONYX PHARMA SA [FR/FR]; 33-43 Av-
enue Georges Pompidou, Batiment D2, 31130 Balma (FR).

(72) Inventor: DASSEUX, Jean-Louis Henri; 7 Allees Charles
Malpel, Bât. B., 31300 Toulouse (FR).

(74) Agent: HOFFMANN EITLE PATENT- UND
RECHTSANWÄLTE PARTMBB, ASSOCIATION
NO. 151; Arabellastraße 30, 81925 Munich (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: COMPOUNDS USEFUL FOR TREATING LIVER DISEASES

(57) Abstract: This invention provides compounds, for example, of Formulae (A)-(H) and (J)-(AA) and pharmaceutically acceptable salts, solvates, esters, amides, and prodrugs thereof. The invention further provides pharmaceutical compositions comprising a compound of the invention, and a pharmaceutically acceptable carrier or vehicle. The compounds and compositions disclosed herein are useful for treating or preventing various diseases and conditions, for example liver disease such as liver fibrosis, fatty liver disease, non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), and kidney diseases such as acute kidney injury (AKI).

WO 2022/189856 A1